Clinical Research Directory
Browse clinical research sites, groups, and studies.
LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients
Sponsor: European Institute of Oncology
Summary
This is a cross-sectional and retrospective study of a cohort of patients with invasive lobular breast cancer (LBC) or in situ lobular neoplasia (LIN3). The main endpoint is the relative frequency of patients with a germline mutation using a recent panel including 113 genes from the "Illumina" protocol. In case of identification of a novel pathogenetic germline mutations, a personalized follow-up will be offered to each patient (in case of genes at moderate-, low-penetrance), or prophylactic mastectomy (in case of genes at high-penetrance). Breast screening in moderate-, low-penetrance mutated patients should be performed periodically using digital mammography, ultrasound and MRI, and will be routinely observed. Patients will be scheduled for follow-up at six-month intervals for 5 years at our outpatient clinic, and yearly thereafter
Key Details
Gender
FEMALE
Age Range
18 Years - 99 Years
Study Type
OBSERVATIONAL
Enrollment
800
Start Date
2022-05-16
Completion Date
2026-05-16
Last Updated
2025-12-04
Healthy Volunteers
No
Interventions
Illumina panel
Determination of germline mutations using a recent panel including 113 genes from the "Illumina" protocol
Locations (1)
European Institute of Oncology
Milan, Italy